NetScientific (NSCI), an international life sciences and sustainability technology investment and commercialisation Group, reported on 7 November that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), will present clinical data from two Phase II clinical trials of its lead candidate PDS0101 - being developed as a potential treatment for HPV-positive cancers. The data will be presented at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022) being held ....
08 Nov 2022
WH Ireland: NetScientific (NSCI) - PDS Biotech to present data to the Annual Meeting for the Society for Immunotherapy of Cancer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WH Ireland: NetScientific (NSCI) - PDS Biotech to present data to the Annual Meeting for the Society for Immunotherapy of Cancer
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
08 Nov 2022 -
Author:
Matthew Davis | Emma Ulker -
Pages:
5
NetScientific (NSCI), an international life sciences and sustainability technology investment and commercialisation Group, reported on 7 November that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), will present clinical data from two Phase II clinical trials of its lead candidate PDS0101 - being developed as a potential treatment for HPV-positive cancers. The data will be presented at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022) being held ....